Published on 16.06.16 in Vol 5, No 2 (2016): Apr-Jun
Using Social Media Data to Identify Potential Candidates for Drug Repurposing: A Feasibility Study
Background: Drug repurposing (defined as discovering new indications for existing drugs) could play a significant role in drug development, especially considering the declining success rates of developing novel drugs. Typically, new indications for existing medications are identified by accident. However, new technologies and a large number of available resources enable the development of systematic approaches to identify and validate drug-repurposing candidates. Patients today report their experiences with medications on social media and reveal side effects as well as beneficial effects of those medications.
Objective: Our aim was to assess the feasibility of using patient reviews from social media to identify potential candidates for drug repurposing.
Methods: We retrieved patient reviews of 180 medications from an online forum, WebMD. Using dictionary-based and machine learning approaches, we identified disease names in the reviews. Several publicly available resources were used to exclude comments containing known indications and adverse drug effects. After manually reviewing some of the remaining comments, we implemented a rule-based system to identify beneficial effects.
Results: The dictionary-based system and machine learning system identified 2178 and 6171 disease names respectively in 64,616 patient comments. We provided a list of 10 common patterns that patients used to report any beneficial effects or uses of medication. After manually reviewing the comments tagged by our rule-based system, we identified five potential drug repurposing candidates.
Conclusions: To our knowledge, this is the first study to consider using social media data to identify drug-repurposing candidates. We found that even a rule-based system, with a limited number of rules, could identify beneficial effect mentions in patient comments. Our preliminary study shows that social media has the potential to be used in drug repurposing.
JMIR Res Protoc 2016;5(2):e121
Crowdfunding campaign to support this specific research
We help JMIR researchers to raise funds to pursue their research and development aimed at tackling important health and technology challenges. If you would like to show your support for this author, please donate using the button below. The funds raised will directly benefit the corresponding author of this article (minus 8% admin fees). Your donations will help this author to continue publishing open access papers in JMIR journals. Donations of over $100 may also be acknowledged in future publications.
Suggested contribution levels: $20/$50/$100
New drug development costs US $500 million to $2 billion and takes 10-15 years . A well-known approach to reduce risk and cost of new drug development is drug repurposing (or drug repositioning) [ ]. Drug repurposing (defined as discovering new indications for existing drugs) could play a significant role in drug development, considering the declining success rates of developing novel drugs. From 2007-2009, 30-40% of newly approved drugs were repurposed medications [ ]. Considering the high cost of launching a new drug, this emphasis on repurposing could markedly affect drug development. Typically, a new indication for an available drug is identified by chance. However, new technologies and a large number of available resources enable the development of systematic approaches to identify and validate drug repurposing candidates with considerably lower costs. Drug repurposing has been exhaustively studied, and various approaches have been used [ - ] to identify novel drug repurposing candidates, using clinical data [ ], genetic information [ - ], and scientific literature [ - ].
Grau and Serbedzija  named two types of drug repurposing: (1) identification of off-target drug actions and (2) identification of relevance of a known drug target to a new disease. From an informatics perspective, freely available and relevant resources such as scientific literature, clinical trials, and biological resources can be used to conduct drug-repurposing studies. The compound database PubChem [ ] has been used in several drug-repurposing studies [ ]. Hoehndorf et al [ ] implemented a system that inferred novel associations between drugs and diseases by linking drug-gene associations in the PharmGKB database to phenotype studies and animal models of disease. Moriaud et al [ ] presented a computational method that mined the Protein Data Bank [ ] to identify drug repositioning candidates. Several studies [ , , , , , ] considered literature mining for drug repurposing; this approach has been comprehensively reviewed elsewhere [ , ].
Social media provides a platform for patients to share their experiences with illnesses, medications, and also medical centers . Patient posts, usually written in an informal language, contain hidden and valuable information. Owing to the massive amount of data derived from social media, computerized systems are needed to analyze and extract useful information from patient experience. Unlike scientific literature, these comments are usually written by non-experts users who do not have any obligation to follow proper grammar in their comments or report accurate observation. These differences make mining social media more complicated and challenging compared to scientific literature. Nevertheless, there have been several attempts to extract knowledge from social media. Leaman et al [ ] examined comments posted in a medical forum to identify reported adverse drug events. After manually annotating a corpus of patient posts, they used natural language processing methods to develop a system that extracted adverse drug reactions from the text. Chee et al [ ] studied patient posts on Health and Wellness Yahoo! groups and applied common natural language processing methods to predict adverse drug events and identify medications that might require further scrutiny by the Food and Drug Administration. Freifeld et al [ ] evaluated the correlation between adverse drug events reported in Twitter (where statements are limited to 140 characters) and spontaneous reports received by a regulatory agency. Rastegar et al [ ] implemented a binary classifier to identify adverse drug reactions in tweets. Sharif et al [ ] proposed a sentiment classification framework to detect adverse drug reactions in medical blogs and forums. Recently, Karimi et al [ ] provided a corpus of 1321 medical forum posts on patient-reported adverse drug events, which allows researchers to develop and evaluate pharmacovigilance systems.
Although patients mostly use medically oriented social media to describe adverse events associated with drugs [, ], their experiences may help others to conceive of new indications for existing medications if their descriptions also include beneficial effects. A well-known example is Zolpidem, an insomnia medication that, through social media and patient reviews, was subsequently used for brain injury [ ]. Leaman at el [ ] identified 157 beneficial effects, in 3600 patient posts that could lead to drug repurposing. The accuracy of these reported beneficial effects in social media may be questionable, but considering the value of drug repurposing and huge amount of available social media data, it is worthwhile to study this type of information and investigate the possibility of identifying potential drug-repurposing candidates. In this study, we assessed the feasibility of using social media data in identifying potential drug repurposing candidates. Our hypothesis is that this imperfect resource could lead to drug repurposing.
In this study, we used data from four public resources: WebMD , DrugBank [ ], SIDe Effect Resource (SIDER) [ ], and Unified Medical Language System (UMLS) [ ]. Below are brief descriptions of the resources and their uses in this research.
WebMD is an US corporation that provides Web-based health-related services, including a forum for patients to share their experiences with medications. The comments are entered as free text, and the length of comments is not subject to a character or word count limit. WebMD  allows users to score three different aspects of the medication in their reviews: (1) effectiveness, (2) ease of use, and (3) satisfaction. WebMD provides some basic information about the users such as age, sex, and duration of treatment. The patient comments from WebMD were the main material used in this study.
DrugBank is a bioinformatics and cheminformatics resource that provides drug information, such as indication, synonyms, gene target, drug interactions, and structure. This database was used to identify known indications of drugs.
SIDER, developed by Kuhn et al , contains information about 1430 marketed medications and 5880 side effects (140,064 drug-side effect pairs) extracted from public documents and package inserts. SIDER retrieved adverse drug reaction and disease names from UMLS to generate a dictionary of side effects. We used SIDER to detect known side effects of drugs mentioned in the comments.
UMLS  integrates medical terminology and coding standards to help researchers and developers create interoperable biomedical information systems. We used UMLS resources to create a dictionary of disease names. The dictionary contains all spelling variants of diseases provided in UMLS. The dictionary includes 239,227 entries for 86,839 unique diseases.
In the first step, we generated a list of the top 180 most frequently searched medications on WebMD. All patient comments pertaining to these drugs were retrieved. Through DrugBank, we collected known and approved indications related to those medications. To locate the drugs in DrugBank, we searched synonyms and brand name entries in addition to drug name entry. In the next step, a list of known side effects for each drug is retrieved from SIDER.
We next developed a natural language processing system to identify beneficial or adverse effects. Any mention of disorders in the reviews was tagged by using two disease named entity recognition (NER) approaches: (1) dictionary-based and (2) machine learning. In the dictionary-based approach, a list of disease names from UMLS was retrieved and a string-matching technique was applied to identify diseases mentioned in the comments. The dictionary-based approach did not consider any grammatical or semantic reasoning or spelling errors. For the machine-learning NER approach, we used MetaMap , a tool to recognize UMLS concepts (eg, diseases) in the text. Unlike the dictionary-based method, MetaMap uses natural language processing and computational linguistic techniques to incorporate semantic and grammatical reasoning in the identification task.
We discarded comments that contained only known indications or adverse effects for related medication. We then manually reviewed some of the remaining comments to develop a list of textual patterns commonly used to report beneficial effects or indications. We developed a rule-based system to tag the comments containing at least one of those patterns. In the final step, the tagged comments were manually reviewed to identify potential drug repurposing candidates.
We retrieved 64,616 patient posts from the top 180 most commonly searched drugs in WebMD (mean number of posts per drug was 358). Lisinopril (an angiotensin-converting enzyme inhibitor used to treat high blood pressure and heart failure) had the most comments (n=2931), whereas metoclopramide (used to treat gastric esophageal reflux disease) had the fewest comments (n=8).shows the top 10 reviewed medications and includes the three most frequently named diseases in the respective comments.
The dictionary-based NER approach identified 2178 disease names in the comments, whereas MetaMap identified 6171 disease mentions.shows the 10 most commonly named diseases in the comments (after disambiguated terms were removed manually). Of the 180 drugs, 164 (91.1%) were listed in DrugBank but only 74 (41.1%) were listed in SIDER. We filtered comments to remove text describing known indications and adverse drug events from the list of recognized disease names; frequently named diseases from the text that remained are shown in (note the overlap with ).
|Drug name||Reviews, n||Disease names, n||Most frequent disease names|
|High blood pressure||Cough|
|Phentermine||1931||207||860||Dry mouth||Dry mouth|
|Dry mouth||1269||Weight gain||3778|
|Mood swing||730||Dry mouth||1279|
|Drug name||Disease names, n||Most frequent disease names|
|High blood pressure||Cough|
|High blood pressure||Sleeping|
|Chronic pain||Back pain|
The frequency of ten common textual patterns, used to report beneficial effects, were counted in the comments and shown in. shows the frequency of the patterns after removing the comments, which mentioned only known side effects or indication. A manual review of the remaining comments identified five drugs with potential for repurposing (see ).
|Pattern||Count||Example drugs and commentsa|
|I use * for||307||Methadone: I use this for diabetic neuopathy. works well with very little side effects.|
|Percocet: I use this for M.S. pain|
|Percocet: I use this med for peripheral neuropathy pain.|
|I use it for||42||Cymbalta: My use of Cymbalta is two fold. I use it for depression and fibromyalgia pain.|
|Spironolactone: I use it for acne. Go figure it works|
|Promethazine: I use it for gastroparesis. I also use it for sleep 4 or 5 times a month|
|It helps with||131||Nucynta: It helps with my pain from surgery|
|Percocet: it helps with my back pain, better then any drug|
|Klonopin: I like this medication it helps with my anxiety.|
|It help with||11||OxyContin: it help with muscle spasms|
|Neurontin: i had drop foot and much pain. it help with the pain along with the 3 epidurals i receiveed in my spine.|
|Cymbalta: i started this medication years ago. not only did it help my depression, it help with my auto immune, muscle and nerve pain.|
|I take it||1,161||Nucynta: I take it for severe headache and neck pain from arthritis, bulging disks, and bone spur in my neck (cervical spine)|
|Methadone: I take it for chronic pain it helps a lot|
|Flexeril: I take it for muscle spasms related to fibromyalgia.|
|I take it for||91||Methadone: I take it for chronic pain it helps a lot|
|Methadone: I take it for degenertive disk deteration in my neck.|
|Hydrocodone-acetaminophen: i take it for my scholiosis of my back|
|It works for||258||Methocarbamol: It works for my muscle tension, but gives me a headache.|
|Diazepam: it works for my pain weal good|
|Tramadol: It works for my Arthritis Pain.|
|It is useful for||0||…|
|Useful for||18||Methadone: very useful for chronic and severe pain associated with fibromyalgia/rheumatoid arthritis.|
|Effexor: I have been reading the reviews of this med. I have been using it for 1.5 yrs and has been very useful for my depression.|
|Ultram: this med has been very useful for my hip and back pain.|
|Prescribed for||319||Percocet: I was prescribed for kidney stones. definately took the pain away and very high.|
|Zoloft: I feel like the antidepressant is used in conjunction with my cymbalta which I am prescribed for both depression and fibromayalgia.|
|Celebrex: I was prescribed for knee pain following surgery for torn muniscus.|
aConsumer comments are shown exactly as they appeared on the WebMD site.
|Pattern||Count||Example drugs and commentsa|
|I use * for||171||Flector: it’s not so bad. I use them for stress headaches only if I have a mild headache|
|Hydroxyzine: I use this drug for itching attacks and it works fast and effective for me.|
|Elavil: I use this medication for restless leg syndrom|
|I use it for||23||Promethazine: I use it for gastroparesis.i also use it for sleep 4 or 5 times a month|
|Amitriptyline: I use it for ic|
|Seroquel: I m in love with seroquel its amazing! I use it for sleep and I wake up refreshed|
|It helps with||72||Neurontin: it helps with numbness in my legs and arms|
|Neurontin: I was diagnosed with rsd in from a fall on the ice. It helps with controlling the pain;|
|Seroquel: although it helps with my depression I have gained over 50lbs|
|It help with||6||Oxycontin: it help with muscle spasms|
|Hydrocodone-acetaminophen: it is ok I think and it help with my back pian.|
|Neurontin: I had drop foot and much pain. It help with the pain along with the 3 epidurals I receiveed in my spine.|
|I take it||729||Methadone: I take it for chronic pain it helps alot|
|Pristiq: I take it for depression and ptsd as well as for chronic pain from failed cervical fusion.|
|Zoloft: I have taken it for three years almost and when I take it my depression worsens rather in the summer when I wouldnt take it I was the happiest|
|I take it for||48||Percocet: I take it for pain after a shoulder surgery and it works|
|Buspar: I take it for stress.|
|Effexor: I take it for depression.|
|It works for||155||Pristiq: I do not think it works for me makes me very consipated and I think it makes the back of my legs hurt in the muscle part.|
|Metformin: I take it before bed no sideeffect so for taking one month hope it works for me yes I am scared|
|Flexeril: back problems healed up then came right back. overall it works for a little while.|
|Useful for||13||Effexor: I have been reading the reviews of this med. I have been using it for 1.5 yrs and has been very useful for my depression.|
|Hydrocodone-acetaminophen: this med. is useful for short term relief of pain.|
|Ultram: this med has been very useful for my hip and back pain.|
aConsumer comments are shown exactly as they appeared on the WebMD site.
|Medication||Indication||Adverse effect||Patient commentsa|
|Methadone||Dry cough, drug withdrawal syndrome, opioid type drug dependence, and pain||Amenorrhea, phlebitis, sneezing, suffering, withdrawn, hypomagnesemia, urticaria, rhinorrhea, fever, spasm, …||I use this for diabetic neuopathy. Works well with very little side effects.|
|Elavil||Depression, chronic pain, irritable bowel syndrome, sleep disorders, diabetic neuropathy, agitation and insomnia, and migraine prophylaxis||None in SIDER||elavil is an old school antidepressant that is now considered a dirty drug because of its undesired side effects. one of the unintended side effects is to relax the skeletal muscle tissue. I use elavil off label to treat my tmj|
|Spironolactone||Low-renin hypertension, hypokalemia, and Conn syndrome||Hyperkalemia, amenorrhea, urticaria, epidermal necrolysis, anaphylaxis, fever, toxic epidermal necrolysis, lethargy, nausea, …||I use it for acne. go figure it works|
|Strattera||Attention-deficit/hyperactivity disorder, alone or in combination with behavioral treatment||None in SIDER||I was prescribed this medication for slight adhd with off label anxiety help.|
|Viibryd||Acute episodes of major depression||None in SIDER||It even helps my migraines somewhat (maybe it will be off label in the future for migraine prophylaxis)|
aConsumer comments are shown exactly as they appeared on the WebMD site.
Comparison of MetaMap Versus Dictionary-Based Approach
MetaMap is a sophisticated tool that uses natural language processing and machine learning methods; thus, it is more accurate than the dictionary-based approach. MetaMap, to some extent, tackled some general concerns such as disambiguation, misspelling, and word normalization, but none of these is addressed in the dictionary-based approach. For example, in the phrase “My stomach and back hurts to sit, lay down, or stand,” the dictionary-based approach would tag “down” as a disease because of overlap with the “genetic disorder down syndrome.” Asshows, MetaMap recognized about three times the number of disease names than the dictionary-based approach. The main reason for this difference is word normalization in MetaMap. The dictionary-based approach is limited by its requirement for exact matches—for example, a dictionary that contains only “dizzy” would not detect “dizziness” as a relevant word. In contrast, MetaMap uses stemming and lemmatization to normalize words. The main advantage of dictionary-based mapping over MetaMap is speed (the dictionary-based approach is considerably faster).
Using Patient Comments for Drug Repurposing
The reviews commonly described general disorders such as pain, itching, and headache. This is expected because comments usually are not authored by medical experts. We observed that patients tend to report adverse drug events instead of beneficial effects, as some of the previous studies reported a similar trend . For example, in the corpus provided by Leaman et al [ ], they annotated 157 beneficial effects in 3600 posts, while they found 1260 adverse drug events. Nevertheless, some patient comments contain beneficial effects of medication, which makes social media a useful resource for drug repurposing. This imbalance distribution makes identifying beneficial effects more difficult, especially for training a classifier. Our results (see , , and 6) suggest that an effective approach for this task is to recognize the textual patterns that people used to report beneficial effects (eg, “I use [drug] for [disease]”). For example, in a review of Viibryd , a user mentioned, “It even helps my migraines somewhat,” clearly noting a beneficial effect of the drug, which could be captured by our rule-based system. Similar to other computational drug repurposing approaches, these findings need to be reviewed manually by experts and then confirmed or rejected by laboratory tests or clinical trials. But as these reviews provided by non-expert users, compared to other drug repurposing studies, which use resources provided or generated by experts such as clinical data or biomedical literature, our findings need more validation before going through clinical trials or laboratory tests.
We acknowledge some limitations to this study. Analysis of the patient comments, which are written in an informal manner, obviously needs a system that can handle spelling and grammatical errors. Our current implementation does not address these issues.
Our system covered only simple textual patterns, although examples inand highlight the need to decode complex patterns. A simple pattern-matching system obviously is insufficient for a statement such as “I use it for nose allergies and it does not clear up my nostrils.” A system should be able to handle negation and coreference.
Another limitation of this study was that comments originated from only one forum. Other social media sites such as Yahoo! Answers, PatientsLikeMe , and even Twitter have similar information, which can be studied and added to our corpus. In addition, using only one resource for known side effects and one for indication was another limitation. In , there are several known indications and adverse drug events, which highlight this limitation.
In this study, we were not able to evaluate our system precisely and provide common performance metrics because of the lack of an annotated corpus. As future work, we plan to annotate a corpus of comments from various forums, to allow us to explore this valuable resource extensively and implement and evaluate different approaches.
We assessed the feasibility of using social media to identify drug-repurposing candidates. After collecting patient reviews of medications from WebMD, we used dictionary-based and MetaMap approaches to identify disorders mentioned in the reviews. Reviews describing known indications or known adverse drug events were excluded, and the remaining reviews were searched for textual patterns commonly used to report beneficial effects. Although the most commonly reported disorders were nonspecific (eg, pain, itching, headache), we nevertheless showed that consumer comments contain beneficial effects of medication and have the potential to be used for drug repurposing. Our textual patterns were able to capture some beneficial effects, but there is a need for a more complex and sophisticated system to identify beneficial effects in social media.
This work was supported in part by the National Institute of General Medical Sciences R01 GM102282 and National Library of Medicine R01 LM011934.
Conflicts of Interest
- Adams CP, Brantner VV. Estimating the cost of new drug development: is it really 802 million dollars? Health Aff (Millwood) 2006;25(2):420-428 [FREE Full text] [CrossRef] [Medline]
- Tobinick EL. The value of drug repositioning in the current pharmaceutical market. Drug News Perspect 2009 Mar;22(2):119-125. [CrossRef] [Medline]
- Jin G, Wong STC. Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. Drug Discov Today 2014 May;19(5):637-644 [FREE Full text] [CrossRef] [Medline]
- Grau D, Serbedzija G. Innovative strategies for drug repurposing. Drug Discovery & Development 2005.
- Dudley JT, Deshpande T, Butte AJ. Exploiting drug-disease relationships for computational drug repositioning. Brief Bioinform 2011 Jul;12(4):303-311 [FREE Full text] [CrossRef] [Medline]
- Xu H, Aldrich MC, Chen Q, Liu H, Peterson NB, Dai Q, et al. Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality. J Am Med Inform Assoc 2015 Jan;22(1):179-191 [FREE Full text] [CrossRef] [Medline]
- Sanseau P, Agarwal P, Barnes MR, Pastinen T, Richards JB, Cardon LR, et al. Use of genome-wide association studies for drug repositioning. Nat Biotechnol 2012 Apr;30(4):317-320. [CrossRef] [Medline]
- Rastegar-Mojarad M, Ye Z, Kolesar JM, Hebbring SJ, Lin SM. Opportunities for drug repositioning from phenome-wide association studies. Nat Biotechnol 2015 Apr;33(4):342-345. [CrossRef] [Medline]
- Moosavinasab S, Patterson J, Strouse R, Rastegar-Mojarad M, Regan K, Payne PRO, et al. 'RE:fine drugs': an interactive dashboard to access drug repurposing opportunities. Database (Oxford) 2016 [FREE Full text] [CrossRef] [Medline]
- Wei CP, Chen KA, Chen LC. Mining Biomedical Literature and Ontologies for Drug Repositioning Discovery. Advances in Knowledge Discovery and Data Mining 2014:384.
- Rastegar-Mojarad M, Komandur Elayavilli R, Li D, Prasad R, Liu H. A new method for prioritizing drug repositioning candidates extracted by literature-based discovery. Bioinformatics and Biomedicine (BIBM) 2015:669-674.
- Liu H, Rastegar-Mojarad M. Literature-Based Knowledge Discovery. In: Big Data Analysis for Bioinformatics and Biomedical Discoveries. Boca Raton, FL: CRC Press; 2016:233-248.
- Rastegar-Mojarad M, Komandur Elayavilli R, Li D, Liu H. Assessing the Need of Discourse-Level Analysis in Identifying Evidences for Drug-Disease Relations in Scientific Literature. In: 15th World Congress on Health and Biomedical Informatics. 2015 Presented at: MEDINFO 2015; Aug. 19-23, 2015; Sao Paulo, Brazil.
- Wang Y, Suzek T, Zhang J, Wang J, He S, Cheng T, et al. PubChem BioAssay: 2014 update. Nucleic Acids Res 2014 Jan;42(Database issue):D1075-D1082 [FREE Full text] [CrossRef] [Medline]
- Cheng T, Pan Y, Hao M, Wang Y, Bryant SH. PubChem applications in drug discovery: a bibliometric analysis. Drug Discov Today 2014 Nov;19(11):1751-1756 [FREE Full text] [CrossRef] [Medline]
- Hoehndorf R, Oellrich A, Rebholz-Schuhmann D, Schofield PN, Gkoutos GV. Linking PharmGKB to phenotype studies and animal models of disease for drug repurposing. Pac Symp Biocomput 2012:388-399 [FREE Full text] [Medline]
- Moriaud F, Richard SB, Adcock SA, Chanas-Martin L, Surgand JS, Ben Jelloul M, et al. Identify drug repurposing candidates by mining the protein data bank. Brief Bioinform 2011 Jul;12(4):336-340 [FREE Full text] [CrossRef] [Medline]
- Moriaud F, Doppelt-Azeroual O, Martin L, Oguievetskaia K, Koch K, Vorotyntsev A, et al. Computational fragment-based approach at PDB scale by protein local similarity. J Chem Inf Model 2009 Feb;49(2):280-294. [CrossRef] [Medline]
- Rajpal DK, Qu XA, Freudenberg JM, Kumar VD. Mining emerging biomedical literature for understanding disease associations in drug discovery. Methods Mol Biol 2014;1159:171-206. [CrossRef] [Medline]
- Tari LB, Patel JH. Systematic drug repurposing through text mining. Methods Mol Biol 2014;1159:253-267. [CrossRef] [Medline]
- Xu R, Wang Q. Large-scale extraction of accurate drug-disease treatment pairs from biomedical literature for drug repurposing. BMC Bioinformatics 2013;14:181 [FREE Full text] [CrossRef] [Medline]
- Deftereos SN, Andronis C, Friedla EJ, Persidis A, Persidis A. Drug repurposing and adverse event prediction using high-throughput literature analysis. Wiley Interdiscip Rev Syst Biol Med 2011;3(3):323-334. [CrossRef] [Medline]
- Rastegar-Mojarad M, Ye Z, Wall D, Murali N, Lin S. Collecting and Analyzing Patient Experiences of Health Care From Social Media. JMIR Res Protoc 2015;4(3):e78 [FREE Full text] [CrossRef] [Medline]
- Leaman R, Wojtulewicz L, Sullivan R, Skariah A, Yang J, Gonzalez G. Towards internet-age pharmacovigilance: extracting adverse drug reactions from user posts to health-related social networks. In: BioNLP. 2010 Presented at: BioNLP; 2010; Stroudsburg, PA p. 117-125.
- Chee BW, Berlin R, Schatz B. Predicting adverse drug events from personal health messages. AMIA Annu Symp Proc 2011;2011:217-226 [FREE Full text] [Medline]
- Freifeld CC, Brownstein JS, Menone CM, Bao W, Filice R, Kass-Hout T, et al. Digital drug safety surveillance: monitoring pharmaceutical products in twitter. Drug Saf 2014 May;37(5):343-350 [FREE Full text] [CrossRef] [Medline]
- Rastegar-Mojarad M, Komandur Elayavilli R, Yu Y, Hiu H. Detecting signals in noisy data - can ensemble classifiers help identify adverse drug reaction in tweets? In: Proceedings of the Social Media Mining Shared Task Workshop. 2015 Presented at: Pacific Symposium on Biocomputing; Jan. 4-8, 2015; Big Island, HI.
- Sharif H, Zaffar F, Abbasi A, Zimbra D. Detecting Adverse Drug Reactions Using a Sentiment Classification Framework. Academy of Science and Engineering 2014.
- Karimi S, Metke-Jimenez A, Kemp M, Wang C. Cadec: A corpus of adverse drug event annotations. J Biomed Inform 2015 Jun;55:73-81. [CrossRef] [Medline]
- Harpaz R, DuMouchel W, Shah NH, Madigan D, Ryan P, Friedman C. Novel data-mining methodologies for adverse drug event discovery and analysis. Clin Pharmacol Ther 2012 Jun;91(6):1010-1021 [FREE Full text] [CrossRef] [Medline]
- Yang C, Yang H, Jiang L, Zhang M. Social media mining for drug safety signal detection. 2012 Presented at: International Workshop on Smart Health and Wellbeing; 2012; New York, NY p. 33-40.
- Boggan S. The Guardian. The miracle treatment that's bringing the brain-damaged back to life URL: https://www.theguardian.com/science/2006/sep/12/health.healthandwellbeing [accessed 2016-05-25] [WebCite Cache]
- WebMD. WebMD Drugs & Medications - Medical information on prescription drugs, vitamins and over-the-counter medicines URL: http://www.webmd.com/drugs/index-drugs.aspx [accessed 2016-05-25] [WebCite Cache]
- Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, et al. DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res 2011 Jan;39(Database issue):D1035-D1041 [FREE Full text] [CrossRef] [Medline]
- Kuhn M, Campillos M, Letunic I, Jensen LJ, Bork P. A side effect resource to capture phenotypic effects of drugs. Mol Syst Biol 2010;6:343 [FREE Full text] [CrossRef] [Medline]
- Bodenreider O. The Unified Medical Language System (UMLS): integrating biomedical terminology. Nucleic Acids Res 2004 Jan 1;32(Database issue):D267-D270 [FREE Full text] [CrossRef] [Medline]
- Aronson AR. Effective mapping of biomedical text to the UMLS Metathesaurus: the MetaMap program. Proc AMIA Symp 2001:17-21 [FREE Full text] [Medline]
- PatientsLikeMe. URL: https://www.patientslikeme.com/ [accessed 2016-05-25] [WebCite Cache]
|NER: named entity recognition|
|SIDER: SIDe Effect Resource|
|UMLS: Unified Medical Language System|
Edited by G Eysenbach; submitted 08.02.16; peer-reviewed by M Torii, C Freifeld; comments to author 28.03.16; revised version received 14.04.16; accepted 15.04.16; published 16.06.16
©Majid Rastegar-Mojarad, Hongfang Liu, Priya Nambisan. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 16.06.2016.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Research Protocols, is properly cited. The complete bibliographic information, a link to the original publication on http://www.researchprotocols.org, as well as this copyright and license information must be included.